SeluDex: A phase IB/II open label study of the MEK-inhibitor selumetinib in combination with dexamethasone for paediatric and adult patients with 2nd relapsed precursor B- or T-ALL

Billingham, Lucinda (Co-Investigator)
Kearns, Pamela (Principal Investigator)

Cancer Research UK Clinical Trials Unit

Short title	SeluDex: A phase IB/II open label study of the MEK-inhibitor selumetinib in combination with dexamethasone for paediatric and adult patients with 2nd relapsed precursor B- or T-ALL
Status	Finished
Effective start/end date	1/10/16 → 31/12/24

Funding

INNOVATIVE THERAPIES FOR CHILDREN WITH CANCER (ITCC)
ASTRA ZENECA UK LIMITED
Cancer Research Uk

1 Article
1 Preprint

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial
Menne, T., Slade, D., Savage, J., Johnson, S., Irving, J., Kearns, P., Plummer, R., Shenton, G., Veal, G. J., Vormoor, B., Vormoor, J. & Billingham, L., 4 Mar 2022, In: BMJ open. 12, 3, 12 p., e059872.
Research output: Contribution to journal › Article › peer-review

Open Access
File
110 Downloads (Pure)
Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial
Menne, T., Slade, D., Savage, J., Johnson, S., Irving, J. A. E., Kearns, P. R., Plummer, R., Shenton, G., Veal, G. J., Vormoor, B., Vormoor, J. & Billingham, L., 25 Oct 2021, medRxiv.
Research output: Working paper/Preprint › Preprint